Featured Research

from universities, journals, and other organizations

Increased mortality rates seen in chronic hepatitis C patients with pre-cirrhotic advanced fibrosis

Date:
April 7, 2011
Source:
Wiley-Blackwell
Summary:
A three-year follow-up study of patients in the Hepatitis C Antiviral Long-term Treatment against Cirrhosis trial revealed that increased mortality among patients with advanced chronic hepatitis C who received long-term peginterferon therapy was attributed to non-liver related causes and occurred primarily in patients with bridging fibrosis.

A three-year follow-up study of patients in the Hepatitis C Antiviral Long-term Treatment against Cirrhosis (HALT-C) trial revealed that increased mortality among patients with advanced chronic hepatitis C who received long-term peginterferon therapy was attributed to non-liver related causes and occurred primarily in patients with bridging fibrosis. No pattern to this excess mortality was evident to researchers, but deaths were unrelated to the peginterferon treatment.

Full findings are published in the April issue of Hepatology, a peer-reviewed journal of the American Association for the Study of Liver Diseases (AASLD).

Infection with hepatitis C virus (HCV) is the primary cause of chronic hepatitis in the U.S., and is a major cause of morbidity and mortality resulting from cirrhosis and hepatocellular carcinoma (HCC). According to the Centers for Disease Control and Prevention (CDC), 3.2 million American are infected with chronic HCV which accounts for up to 10,000 deaths annually in the U.S. The standard treatment for chronic HCV is a combination of pegylated interferon and ribavirin -- a combination therapy which achieves sustained virological response rates of 40%-80% as reported by the CDC. Though antiviral therapy may decrease the rate of progression and death from chronic HCV, there is currently no beneficial therapy available for patients who fail to respond to standard treatment.

The initial HALT-C Trial -- a randomized, controlled study of 1,050 chronic HCV patients with advanced fibrosis (n=622) or cirrhosis (n=428) who failed to achieve a sustained response from prior antiviral therapy -- evaluated the effects of low-dose maintenance therapy with peginterferon, compared to no therapy, in slowing disease progression and preventing end-stage liver disease, HCC, and death. The results from the randomized phase showed that long-term peginterferon treatment failed to produce a positive effect on clinical outcomes or death. Furthermore, the authors noted that excess mortality occurred in the treatment group among patients with advanced fibrosis without cirrhosis.

"We followed the trial participants for an additional three years to investigate whether the increased mortality persisted and to explore causes of death," said lead study author Adrian Di Bisceglie, MD, FACP, Chairman of the Department of Internal Medicine at Saint Louis University School of Medicine in Missouri. For the current analysis, a committee of investigators reviewed deaths occurring during and after the HALT-C Trial to determine the cause of death. The committee categorized each death as liver- or non-liver related, and whether or not the death was associated with complications of peginterferon.

Analysis showed that 18% of the trial participants died (122) or underwent liver transplantation (74) over a median of 5.7 years. Two thirds of the deaths (62%) were attributed to end-stage liver disease or HCC and the remaining deaths (38%) were attributed to non-liver-related causes. The cumulative seven-year mortality rate was 20% for patients in the treatment group compared to 15% in the non-treatment control. Researchers observed differences in mortality rates (by seven years) between the treatment and non-treatment groups which were statistically significant for patients with fibrosis (14% and 7%, respectively) compared to those with cirrhosis (28% and 26%, respectively).

Researchers noted that the increase in mortality for patients treated with peginterferon did not emerge until three years into treatment and continued for several years after treatment ceased. The excess mortality in the treatment group was mainly linked to non-liver-related causes. "No specific cause of death accounted for the excess mortality, but deaths were unrelated to direct effects of peginterferon treatment," concluded Dr. Di Bisceglie. Researchers could not identify an excess frequency of any single condition or disease category for cause of non-liver related deaths. Only one death was determined to be a probable result of complications from peginterferon therapy. "Our findings suggest that the long-term use of peginterferon should be evaluated cautiously and that attention to unrelated complications is warranted."


Story Source:

The above story is based on materials provided by Wiley-Blackwell. Note: Materials may be edited for content and length.


Journal Reference:

  1. Adrian M. Di Bisceglie, Anne M. Stoddard, Jules L. Dienstag, Mitchell L. Shiffman, Leonard B. Seeff, Herbert L. Bonkovsky, Chihiro Morishima, Elizabeth C. Wright, Kristin K. Snow, William M. Lee, Robert J. Fontana, Timothy R. Morgan, Marc G. Ghany. Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon. Hepatology, 2011; DOI: 10.1002/hep.24169

Cite This Page:

Wiley-Blackwell. "Increased mortality rates seen in chronic hepatitis C patients with pre-cirrhotic advanced fibrosis." ScienceDaily. ScienceDaily, 7 April 2011. <www.sciencedaily.com/releases/2011/04/110407101623.htm>.
Wiley-Blackwell. (2011, April 7). Increased mortality rates seen in chronic hepatitis C patients with pre-cirrhotic advanced fibrosis. ScienceDaily. Retrieved October 22, 2014 from www.sciencedaily.com/releases/2011/04/110407101623.htm
Wiley-Blackwell. "Increased mortality rates seen in chronic hepatitis C patients with pre-cirrhotic advanced fibrosis." ScienceDaily. www.sciencedaily.com/releases/2011/04/110407101623.htm (accessed October 22, 2014).

Share This



More Health & Medicine News

Wednesday, October 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Orthodontist Mom Jennifer Salzer on the Best Time for Braces

Orthodontist Mom Jennifer Salzer on the Best Time for Braces

Working Mother (Oct. 22, 2014) Is your child ready? Video provided by Working Mother
Powered by NewsLook.com
U.S. Issues Ebola Travel Restrictions, Are Visa Bans Next?

U.S. Issues Ebola Travel Restrictions, Are Visa Bans Next?

Newsy (Oct. 22, 2014) Now that the U.S. is restricting travel from West Africa, some are dropping questions about a travel ban and instead asking about visa bans. Video provided by Newsy
Powered by NewsLook.com
US to Track Everyone Coming from Ebola Nations

US to Track Everyone Coming from Ebola Nations

AP (Oct. 22, 2014) Stepping up their vigilance against Ebola, federal authorities said Wednesday that everyone traveling into the US from Ebola-stricken nations will be monitored for symptoms for 21 days. (Oct. 22) Video provided by AP
Powered by NewsLook.com
Doctors Help Paralysed Man Walk Again, Patient in Disbelief

Doctors Help Paralysed Man Walk Again, Patient in Disbelief

AFP (Oct. 22, 2014) Polish doctors describe how they helped a paralysed man walk again, with the patient in disbelief at the return of sensation to his legs. Duration: 1:04 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins